ReviewBMC pulmonary medicine2026
Bronchial Dieulafoy's disease complicated by pulmonary embolism after successful hemostasis: a case report and review of the literature.
Review in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBronchial Dieulafoy's disease (BDD) is a rare vascular anomaly characterized by a large-caliber submucosal artery that can cause sudden, massive, and potentially fatal hemoptysis. Because of its deceptively benign endobronchial appearance, the disease is frequently underrecognized and carries a high risk of catastrophic bleeding following bronchoscopic manipulation. CASE PRESENTATION: A 77-year-old woman without underlying lung disease developed massive hemoptysis and hemorrhagic shock shortly after diagnostic bronchoscopy for an indeterminate endobronchial lesion. Emergency bronchial artery embolization (BAE) achieved effective hemostasis. During recovery, pulmonary embolism was suspected and subsequently confirmed by computed tomography pulmonary angiography (CTPA); the event was classified as intermediate-risk based on right-heart strain and cardiac biomarkers, posing a major therapeutic dilemma regarding anticoagulation after recent life-threatening airway bleeding. After secure hemostasis had been confirmed by the absence of recurrent hemoptysis, stable vital signs and hemoglobin, no further transfusion requirement, and post-embolization angiographic control, anticoagulation was managed through a stepwise strategy: temporary lower-intensity low-molecular-weight heparin followed by escalation to full therapeutic anticoagulation after PE confirmation and clinical stabilization. Follow-up imaging before discharge demonstrated marked resolution of clot burden, and no recurrent hemoptysis occurred during anticoagulation.
conclusionsThis case emphasizes three practical lessons: BDD should be suspected in benign-appearing endobronchial lesions associated with unexplained hemoptysis; bronchoscopic biopsy should be avoided until a vascular lesion is reasonably excluded; and BAE can provide lifesaving hemostasis. In carefully selected patients who develop PE after secure hemostasis, stepwise anticoagulation may be considered under multidisciplinary monitoring, but this single case should be interpreted as hypothesis-generating rather than a generalizable treatment recommendation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.